AbstractBySubCategory

Translational Research

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Correlation of phase 2 trials (Ph2t) results with outcomes of Phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC). Monica Tang

227

Impact of major vascular resection on short- and long-term outcomes in patients with intrahepatic cholangiocarcinoma. Bradley Reames

275

Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. Marcus Smith Noel

276

The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis: A multi-institutional analysis. Aslam Ejaz

277

Molecular biomarkers as predictors of patient survival in pancreatic adenocarcinoma (PDA): An analysis of the Know Your Tumor initiative (KYT). R Joseph Bender

278

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). Eileen Mary O'Reilly

279

Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo). Gary H. Lyman

280

Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial. Jana Kaethe Striefler

281

Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC). Ben George

282

Adjuvant therapy in stage II pancreatic cancer: A National Cancer Database analysis. Aabra Ahmed

283

Tumor interface stability on CT imaging is an early marker of response to cytotoxic therapy in pancreatic ductal adenocarcinoma. Christopher Wilke

284

Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial. Simron Singh

285

Prognostic value of CD8+CD45RO+ tumor-infiltrating lymphocytes (TIL) and PD-L1 in cholangiocarcinoma. Dae Won Kim

286

Precision delivery of RAS-inhibiting siRNA to pancreatic cancer via peptide-based nanoparticles. Matthew S. Strand

287

Association of elevated alpha-1 antitrypsin with advanced clinicopathologic features of hepatocellular carcinoma. Reham Abdel-Wahab

289

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC). Maeve Aine Lowery

290

Next-generation sequencing (NGS) in pancreatic neuroendocrine tumors (panNETs): Defining differentiation and grade genetically. Nitya Prabhakar Raj

291

Combined treatment with TLR7/8 agonists and carbon ion radiation induces local and abscopal immune responses in gastrointestinal tumor models. Peter E Huber

292

Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-FU/LV. Andrea Wang-Gillam

293

A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma. Mitesh J. Borad

294

Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC). Maeve Aine Lowery

295

Evaluation of efficacy of oral administration of pro-drug of triptolide against pancreatic cancer. Vikas Dudeja

296

Multivariate assessment of SPARC expression in resected pancreatic ductal adenocarcinoma to identify subgroups that are sensitive to adjuvant gemcitabine. Steve Kalloger

297

Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma. Sadakatsu Ikeda

298

Profiling of small intestine neuroendocrine tumors to reveal characteristic miRNAs detectable in plasma. Michaela Bowden

299

Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use. Geraldine Perkins

300

Preclinical study of c-Met inhibitor as an adjuvant treatment for hepatocellular carcinoma with macroscopic portal vein invasion. Takashi Kokudo

301

RNA profiling of neuroendocrine tumors (NETs) to define new targets and mechanisms of progression. Namrata Vijayvergia

302

Efficacy and safety of liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial. Li-Tzong Chen

303

Overcoming erlotinib resistance with STAT3 inhibition in pancreatic cancer. Matthew Philip Salzberg

304

Analysis of prior malignancies in patients with cholangiocarcinoma. Taryn Mary Boucher

305

A phase I study of ADH-1 with cisplatin (Cisp) and gemcitabine (Gem) in patients (Pts) with unresectable or metastatic pancreatic and biliary tract cancers. Lyudmyla Derby Berim

306

Genetic difference between multicentric carcinogenesis and intrahepatic metastasis of multiple hepatocellular carcinoma. Yutaka Midorikawa

307

ATM as a biomarker for DNA damage repair deficiency in pancreatic ductal adenocarcinoma. Talia Golan

308

Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). Masafumi Ikeda

309

Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC). Chigusa Morizane

310

Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus. Robin Kate Kelley

311

Germline mutations in seemingly sporadic pancreatic cancer. Cavin Wong

312

Clinical utilization of targetable molecular results in pancreatic cancer: Longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. Lorraine A. Chantrill

314

Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC). Dana Backlund Cardin

315

Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC). Austin G. Duffy

316

Homologous recombination deficiency (HRD) in patients with pancreatic cancer (PC) and response to chemotherapy. Safi Shahda

317

Monitoring tumor specific mutations in plasma during systemic treatment of biliary tract cancer. Lars Henrik Jensen

318

Preoperative vascular grading in patients undergoing surgery for pancreatic cancer: Does radiologic arterial or venous involvement predict margin status? Sanjay S. Reddy

319

Population pharmacokinetics (popPK) to evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure in REG studies including patients with hepatocellular carcinoma (HCC). Bart Ploeger

320

The impact of SPARC expression in survival of pancreatic ductal adenocarcinoma patients after curative resection. Masaaki Murakawa

321

Association of hyaluronan accumulation with clinical-pathologic features in pancreatic ductal adenocarcinomas. Brent K Larson

322

Expression of GRP78 protein in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Asha R. Dhanarajan

323

Immune analysis of fibrolamellar hepatocellular carcinoma. Mehmet Akce

324

Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study. Hannah Marie Cherniawsky

325

Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors for locally advanced pancreatic cancer patients. Byung Min Lee

326

Expression of exportin 1 (XPO1/CRM1) in pancreatic adenocarcinoma. David M Saulino

327

Result of Arid1a deletion on intraductal papillary mucinous neoplasm formation. Sam C. Wang

328

The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance. Jennifer Stern

329

A phase II study of gemcitabine as adjuvant treatment for biliary tract cancer after surgical resection. Sang Myung Woo

330

Targeted pancreatic cancer drug-delivery utilizing sigma-2 ligand/receptor internalization is energy-dependent. Linda X Jin

331

A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer. Jin Yong Patrick Park

332

Prognostic factor of distal bile duct cancer (DBDC) and ampullary cancer (AC) after pancreatoduodenectomy. Shinjiro Tomiyasu

333

The clinical significance of KRAS monitoring in tumor tissues and blood of patients with pancreatic tumor. Fumiaki Watanabe

334

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. Dirk Walter

335

Preclinical antitumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) and utilization as a foundation of front-line pancreatic cancer regimens. Daniel F. Gaddy

336

Expression of estrogen receptor beta isoforms in pancreatic adenocarcinoma. Mamoun Younes

337

Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer. Mark Ricigliano

338

CA19-9-low and Lewis(+) pancreatic cancer: A unique subtype. Guopei Luo

339

Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer. Davide Melisi

TPS501

Pilot skin microbiome study of patients with pancreatic cancer in comparison to patients with other malignancies as well as those without cancer. Erkut Hasan Borazanci

TPS502